Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Axsome Therapeutics Inc AXSM

Healthcare
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AXSM)

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire 9 days ago

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire April 10, 2024

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

GlobeNewswire April 1, 2024

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

GlobeNewswire March 25, 2024

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

GlobeNewswire March 25, 2024

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

GlobeNewswire March 19, 2024

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire March 5, 2024

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire February 27, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 20, 2024
View More News ››

Opinion & Analysis (NDAQ:AXSM)

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Streetwise Reports July 2, 2020

Biopharma to Accelerate Alzheimer Trial Completion

Streetwise Reports March 26, 2020

Two Stock-Moving Catalysts Expected in March for Biopharma

Streetwise Reports February 26, 2020

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

Streetwise Reports January 6, 2020

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Streetwise Reports December 17, 2019

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Streetwise Reports December 4, 2019
View More Opinion ››

Bullboard Posts (NDAQ:AXSM)

Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex

NEWS: $AXSM Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones...
whytestocks - February 20, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 202

BREAKING NEWS: $AXSM Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateTotal...
whytestocks - February 20, 2024

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK!

5 MOST PROMISING ALZHEIMER’S DISEASE STOCK! https://www.aviseanalytics.com/5-most-promising-alzheimers-disease-stock/
AviseAnalytics - June 22, 2021

RE:Awesome Run to Over $100 USD

Now 74$. First over 100 soon then?
Marphine - February 12, 2021

Awesome Run to Over $100 USD

We did great buying below $10 We think GNPX will do the same if not better :-) Same pattern https://finance.yahoo.com/quote/GNPX?p=GNPX ...
winemerlotcab67 - February 23, 2020
View more Bullboard ››

Nextech3D.ai

Nextech3D.ai

Nextech3D.ai is a diversified technology company that leverages proprietary artificial intelligence (AI) to create 3D models ...
View More »